We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC... Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. Show more
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified...
- Positive HTA recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patients with this rare liver disorder - LIVMARLI is the first and only...
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN...
- FDA approval based on MARCH Phase 3 study with highly statistically significant (p<0.0001) reduction in pruritus severity between LIVMARLI vs. placebo - Label covers broad range of PFIC...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 8, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and...
- Results demonstrate 70% risk reduction for long-term clinical outcomes in patients with Alagille syndrome (ALGS) treated with LIVMARLI (p<0.0001) - Data are the first to demonstrate a...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.17 | 4.99786416062 | 23.41 | 25.01 | 23.14 | 429176 | 24.26198637 | CS |
| 4 | -0.35 | -1.40393100682 | 24.93 | 26.61 | 23.14 | 440517 | 24.87076413 | CS |
| 12 | -1.59 | -6.0756591517 | 26.17 | 30.23 | 23.14 | 499409 | 26.77674817 | CS |
| 26 | -3.19 | -11.4872164206 | 27.77 | 35.56 | 23.14 | 597383 | 28.58804505 | CS |
| 52 | -1.93 | -7.28027159562 | 26.51 | 35.56 | 23.14 | 555421 | 28.27343022 | CS |
| 156 | 5.58 | 29.3684210526 | 19 | 35.56 | 12.82 | 356541 | 24.90511951 | CS |
| 260 | 11.58 | 89.0769230769 | 13 | 35.56 | 6.5126 | 279325 | 23.54942275 | CS |
Ganz
1 year ago
historyperson
1 year ago
Ganz
1 year ago
Cosa
1 year ago
Ganz
2 years ago
ClayTrader
4 years ago
CyrusDaVirus
4 years ago
zc182
4 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
